biostudies-literatureUnknown23(1)Miyawaki Y<h4>Background</h4>While survival of systemic lupus erythematosus (SLE) patients has improved substantially, problems remain in the management of their emotional health. Medium to high-dose glucocorticoid doses are known to worsen emotional health; the effect is unclear among patients receiving relatively low-dose glucocorticoids. This study aims to investigate the association between low glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS).<h4>Methods</h4>This cross-sectional study drew on data from SLE patients in 10 Japanese institutions. The participants were adult patients with SLE duration of ≥ 1 year who met LLDAS criteria at the study visit from April 2018 through September 2019. The exposure was the daily glucocorticoid dose (mg oral prednisolone).Arthritis research & therapy79https://www.ebi.ac.uk/biostudies/studies/S-EPMC7944592biostudies-literatureAssociation of glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS): a cross-sectional study.PMC7944592Yoshimi RHiramatsu-Asano SFukuhara SKatayama YShimizu SOhashi KMiyawaki YYajima NOhno SWatanabe HKajiyama HShimojima YYamazaki HMatsumoto YWada JMorishita MTakano-Narazaki MIchinose KHayashi KOgawa YSato SAsano YYamamura YSada KEFujiwara MYamamoto YfalseAssociation of glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS): a cross-sectional study.<h4>Background</h4>While survival of systemic lupus erythematosus (SLE) patients has improved substantially, problems remain in the management of their emotional health. Medium to high-dose glucocorticoid doses are known to worsen emotional health; the effect is unclear among patients receiving relatively low-dose glucocorticoids. This study aims to investigate the association between low glucocorticoid doses and emotional health in lupus low disease activity state (LLDAS).<h4>Methods</h4>This cross-sectional study drew on data from SLE patients in 10 Japanese institutions. The participants were adult patients with SLE duration of ≥ 1 year who met LLDAS criteria at the study visit from April 2018 through September 2019. The exposure was the daily glucocorticoid dose (mg oral prednisolone).2021-01-01T00:00:00Z2021 Mar2025-04-18T16:41:39.204Z2021-03-13T08:14:37ZS-EPMC79445923369174610.1186/s13075-021-02466-2